Ferring and the Institut Pasteur collaborate in novel IBD drug development project

This article is over 11 years old

Published the 15 April 2015 Updated 14 October 2016

Ferring Pharmaceuticals a research-driven, specialty biopharmaceutical group and the Institut Pasteur, a non-profit international biomedical research center in Paris (France) today announced a collaboration aimed at identifying and developing bacteriophages to treat patients suffering from inflammatory bowel disease (IBD).